Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Prognostic value of advanced lung cancer inflammation index in head and neck squamous cell carcinoma.

Jank BJ, Kadletz L, Schnöll J, Selzer E, Perisanidis C, Heiduschka G.

Eur Arch Otorhinolaryngol. 2019 Mar 16. doi: 10.1007/s00405-019-05381-0. [Epub ahead of print]

PMID:
30877423
2.

Experience in Intra-arterial Chemotherapy using Two Protocols for the Treatment of OSCC over Two Decades at the University Hospital Vienna.

Eder-Czembirek C, Rechinger S, Kornek G, Selzer E, Seemann R.

Clinics (Sao Paulo). 2018 Oct 18;73:e433. doi: 10.6061/clinics/2018/e433.

3.

UVEAL METASTASIS BASED ON PATIENT AGE IN 1,111 PATIENTS: Comparison of Clinical Features and Outcomes Per Age Category.

Shields CL, Acaba-Berrocal LA, Selzer EB, Mayro EL, Newman JH, Malik K, Welch RJ, Shields JA.

Retina. 2018 Oct 16. doi: 10.1097/IAE.0000000000002364. [Epub ahead of print]

PMID:
30334925
4.

FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer.

Harpain F, Ahmed MA, Hudec X, Timelthaler G, Jomrich G, Müllauer L, Selzer E, Dörr W, Bergmann M, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B, Silberhumer GR.

J Cancer Res Clin Oncol. 2019 Jan;145(1):77-86. doi: 10.1007/s00432-018-2757-7. Epub 2018 Oct 1.

5.

Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin.

Shields CL, Welch RJ, Malik K, Acaba-Berrocal LA, Selzer EB, Newman JH, Mayro EL, Constantinescu AB, Spencer MA, McGarrey MP, Knapp AN, Graf AE, Altman AJ, Considine SP, Shields JA.

Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):81-90. doi: 10.4103/meajo.MEAJO_6_18.

6.

Comparative Analysis of Clinical and Pathological Lymph Node Staging Data in Head and Neck Squamous Cell Carcinoma Patients Treated at the General Hospital Vienna.

Eder-Czembirek C, Erlacher B, Thurnher D, Erovic BM, Selzer E, Formanek M.

Radiol Oncol. 2018 May 11;52(2):173-180. doi: 10.2478/raon-2018-0020. eCollection 2018 Jun.

7.

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.

Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018 Jul 13. Review.

8.

PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.

Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Füreder T, Rajky O, Berghoff AS, Preusser M, Heiduschka G.

Histopathology. 2018 Oct;73(4):573-584. doi: 10.1111/his.13646. Epub 2018 Jul 4.

PMID:
29742291
9.

ÖGRO survey on radiotherapy capacity in Austria : Status quo and estimation of future demands.

Zurl B, Bayerl A, De Vries A, Geinitz H, Hawliczek R, Knocke-Abulesz TH, Lukas P, Pötter R, Raunik W, Scholz B, Schratter-Sehn A, Sedlmayer F, Seewald D, Selzer E, Kapp KS.

Strahlenther Onkol. 2018 Apr;194(4):284-292. doi: 10.1007/s00066-017-1240-8. Epub 2017 Dec 8.

PMID:
29222711
10.

P16 positivity and regression grade predict survival after neoadjuvant radiotherapy of OSCC.

Eder-Czembirek C, Sulzbacher I, Fuereder T, Selzer E.

Oral Dis. 2018 May;24(4):544-551. doi: 10.1111/odi.12814. Epub 2018 Mar 13.

PMID:
29215771
11.

The effect of adjuvant radiotherapy on radial forearm free flap volume after soft palate reconstruction in 13 patients.

Haymerle G, Enzenhofer E, Lechner W, Stock M, Schratter-Sehn A, Vyskocil E, Bachtiary B, Selzer E, Erovic BM.

Clin Otolaryngol. 2018 Apr;43(2):742-745. doi: 10.1111/coa.13042. Epub 2017 Dec 15. No abstract available.

PMID:
29194976
12.

A 5‑year update of patients with HPV positive versus negative oropharyngeal cancer after radiochemotherapy in Austria.

Lill C, Bachtiary B, Selzer E, Mittlboeck M, Thurnher D.

Wien Klin Wochenschr. 2017 Jun;129(11-12):398-403. doi: 10.1007/s00508-017-1171-5. Epub 2017 Feb 15.

13.

CENP-A Modifications on Ser68 and Lys124 Are Dispensable for Establishment, Maintenance, and Long-Term Function of Human Centromeres.

Fachinetti D, Logsdon GA, Abdullah A, Selzer EB, Cleveland DW, Black BE.

Dev Cell. 2017 Jan 9;40(1):104-113. doi: 10.1016/j.devcel.2016.12.014.

14.

Erratum to "Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival" [Oral Oncol. 60 (2016) 1-7].

Eder-Czembirek C, Czembirek C, Selzer E.

Oral Oncol. 2016 Dec;63:e8. doi: 10.1016/j.oraloncology.2016.10.016. Epub 2016 Oct 31. No abstract available.

PMID:
27810259
15.

Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.

Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.

Oncotarget. 2016 Oct 25;7(43):69976-69990. doi: 10.18632/oncotarget.12099.

16.

Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival.

Eder-Czembirek C, Czembirek C, Selzer E.

Oral Oncol. 2016 Sep;60:1-7. doi: 10.1016/j.oraloncology.2016.06.014. Epub 2016 Jun 28. Erratum in: Oral Oncol. 2016 Dec;63:e8.

PMID:
27531866
17.

Pre-therapeutic fibrinogen levels are of prognostic significance in locally advanced head and neck cancer.

Selzer E, Grah A, Heiduschka G, Kornek G, Thurnher D.

Wien Klin Wochenschr. 2016 May;128(9-10):320-8. doi: 10.1007/s00508-016-0963-3. Epub 2016 Feb 26.

PMID:
26919854
18.

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.

Grunt TW, Hebar A, Laffer S, Wagner R, Peter B, Herrmann H, Graf A, Bilban M, Posch M, Hoermann G, Mayerhofer M, Eisenwort G, Zielinski CC, Selzer E, Valent P.

Am J Cancer Res. 2015 Jan 15;5(2):560-74. eCollection 2015.

19.

Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems.

Selzer E, Grah A, Heiduschka G, Kornek G, Thurnher D.

Strahlenther Onkol. 2015 Jun;191(6):486-94. doi: 10.1007/s00066-014-0803-1. Epub 2015 Jan 13.

PMID:
25583136
20.

Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy.

Heiduschka G, Grah A, Oberndorfer F, Kadletz L, Altorjai G, Kornek G, Wrba F, Thurnher D, Selzer E.

Strahlenther Onkol. 2015 Mar;191(3):209-16. doi: 10.1007/s00066-014-0753-7. Epub 2014 Sep 25.

PMID:
25252603
21.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

PMID:
25188816
22.

Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab.

Heiduschka G, Grah A, Oberndorfer F, Seemann R, Kranz A, Kornek G, Wrba F, Thurnher D, Selzer E.

Strahlenther Onkol. 2014 Sep;190(9):832-8. doi: 10.1007/s00066-014-0652-y. Epub 2014 Apr 9.

PMID:
24715244
23.

Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments.

Selzer E, Kornek G.

Expert Rev Clin Pharmacol. 2013 Nov;6(6):663-76. doi: 10.1586/17512433.2013.841540. Review.

PMID:
24164614
24.

4-({(Z)-5-[(Z)-3-Eth-oxy-4-hy-droxy-benzyl-idene]-3-methyl-4-oxo-1,3-thia-zolidin-2-yl-idene}amino)-benzoic acid dimethyl-formamide monosolvate.

Kosma P, Selzer E, Mereiter K.

Acta Crystallogr Sect E Struct Rep Online. 2012 Dec 1;68(Pt 12):o3417-8. doi: 10.1107/S1600536812047307. Epub 2012 Nov 24.

25.

The impact of molecular targets in cancer drug development: major hurdles and future strategies.

Hebar A, Valent P, Selzer E.

Expert Rev Clin Pharmacol. 2013 Jan;6(1):23-34. doi: 10.1586/ecp.12.71.

PMID:
23272790
26.

NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.

Hebar A, Rütgen BC, Selzer E.

PLoS One. 2012;7(9):e45015. doi: 10.1371/journal.pone.0045015. Epub 2012 Sep 13.

27.

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.

Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, Greil R, Bachtiary B, Tinchon C, Anderhuber W, Burian M, Kasparek AK, Elsäßer W, Kainz H, Riedl R, Kopp M, Kornek G.

Eur J Cancer. 2013 Jan;49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14.

PMID:
22981499
28.

Survival of patients with pathologic T0N+ oral and oropharyngeal cancer after neoadjuvant therapy and surgery: the minority report.

Perisanidis C, Sulzbacher I, Mittlböck M, Mitchell D, Czembirek C, Seemann R, Ewers R, Schopper C, Selzer E.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Mar;115(3):293-8. doi: 10.1016/j.oooo.2012.03.033. Epub 2012 Aug 30.

PMID:
22939322
29.

[Biological effect and tumor risk of diagnostic x-rays. The "war of the theories"].

Selzer E, Hebar A.

Radiologe. 2012 Oct;52(10):892-7. doi: 10.1007/s00117-012-2336-x. German.

PMID:
22914871
30.

HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer.

Perisanidis C, Savarese-Brenner B, Würger T, Wrba F, Huynh A, Schopper C, Kornek G, Selzer E, Ewers R, Psyrri A, Krainer M, Filipits M.

Oral Dis. 2013 Mar;19(2):206-11. doi: 10.1111/j.1601-0825.2012.01972.x. Epub 2012 Aug 14.

PMID:
22891969
31.

Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer.

Perisanidis C, Wrba F, Brandstetter A, Kornek G, Mitchell D, Seemann R, Selzer E, Ewers R, Filipits M.

Br J Oral Maxillofac Surg. 2013 Apr;51(3):234-40. doi: 10.1016/j.bjoms.2012.06.009. Epub 2012 Aug 11.

PMID:
22889668
32.

Postoperative failure of platelet recovery is an independent risk factor for poor survival in patients with oral and oropharyngeal cancer.

Perisanidis C, Mittlböck M, Schoppmann A, Kornek G, Starlinger P, Stift A, Selzer E, Schopper C, Ewers R.

Clin Oral Investig. 2013 Apr;17(3):913-9. doi: 10.1007/s00784-012-0755-8. Epub 2012 May 29.

PMID:
22643871
33.

Basic principles of molecular effects of irradiation.

Selzer E, Hebar A.

Wien Med Wochenschr. 2012 Feb;162(3-4):47-54. doi: 10.1007/s10354-012-0052-9. Review.

PMID:
22476592
34.

Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.

Vormittag L, Lemaire C, Radonjic D, Kornek G, Selzer E.

Strahlenther Onkol. 2012 Mar;188(3):235-42. doi: 10.1007/s00066-011-0040-9. Epub 2012 Feb 10.

PMID:
22318328
35.

Continuous thrombin infusion leads to a bleeding phenotype in sheep.

Siller-Matula JM, Miller I, Gemeiner M, Plasenzotti R, Bayer G, Mesteri I, Fabry A, Petroczi K, Nöbauer K, Razzazi-Fazeli E, Planchon S, Renaut J, Quehenberger P, Selzer E, Jilma B.

Thromb Res. 2012 Aug;130(2):226-36. doi: 10.1016/j.thromres.2011.09.019. Epub 2012 Jan 30.

PMID:
22289207
36.

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.

Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzinger I, Sperr WR, Valent P.

Haematologica. 2012 Feb;97(2):219-26. doi: 10.3324/haematol.2010.035006. Epub 2011 Oct 11.

37.

Impact of elective neck dissection on regional recurrence and survival in cN0 staged oral maxillary squamous cell carcinoma.

Poeschl PW, Seemann R, Czembirek C, Russmueller G, Sulzbacher I, Selzer E, Nuhic D, Ewers R.

Oral Oncol. 2012 Feb;48(2):173-8. doi: 10.1016/j.oraloncology.2011.09.006. Epub 2011 Oct 4.

PMID:
21974917
38.

Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.

Selzer E, Liederer S, Lemaire C, Kren G, Radonjic D, Kornek G, Knocke T, Pötter R, Bachtiary B.

Strahlenther Onkol. 2011 Jun;187(6):373-7. doi: 10.1007/s00066-011-2217-7. Epub 2011 May 16.

PMID:
21603990
39.

Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced.

Lill C, Kornek G, Bachtiary B, Selzer E, Schopper C, Mittlboeck M, Burian M, Wrba F, Thurnher D.

Wien Klin Wochenschr. 2011 Apr;123(7-8):215-21. doi: 10.1007/s00508-011-1553-z. Epub 2011 Mar 30.

PMID:
21448626
40.

Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies.

Weichselbaumer M, Willmann M, Reifinger M, Singer J, Bajna E, Sobanov Y, Mechtcherikova D, Selzer E, Thalhammer JG, Kammerer R, Jensen-Jarolim E.

Version 2. PLoS Curr. 2011 Mar 16 [revised 2011 Jan 1];3:RRN1223.

41.

Perceptions of U.S. physicians regarding the entry-level doctoral degree in physician assistant education.

Muma RD, Smith BS, Anderson N, Richardson M, Selzer E, White R.

J Allied Health. 2011 Spring;40(1):25-33. Review.

PMID:
21399849
42.

[Tumor stem cell research - basis and challenge for diagnosis and therapy].

Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, Hubmann R, Shehata M, Marian B, Selzer E, Pfeilstöcker M, Pittermann E, Jäger U, Pehamberger H, Zielinski C, Valent P.

Wien Klin Wochenschr. 2010 Jul;122(13-14):423-36. doi: 10.1007/s00508-010-1408-z. Epub 2010 Jul 22. Review. German.

PMID:
20645015
43.

Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines.

Eder-Czembirek C, Erovic BM, Czembirek C, Brunner M, Selzer E, Pötter R, Thurnher D.

Strahlenther Onkol. 2010 Mar;186(3):143-8. doi: 10.1007/s00066-010-2069-6. Epub 2010 Feb 22.

PMID:
20339825
44.

Impact of molecular targets in cancer drug development: historical influence and future perspectives.

Selzer E.

Expert Rev Clin Pharmacol. 2010 Mar;3(2):161-3. doi: 10.1586/ecp.10.8. No abstract available.

PMID:
22111562
45.

Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis.

Blüml S, Binder NB, Niederreiter B, Polzer K, Hayer S, Tauber S, Schett G, Scheinecker C, Kollias G, Selzer E, Bilban M, Smolen JS, Superti-Furga G, Redlich K.

Arthritis Rheum. 2010 Jun;62(6):1608-19. doi: 10.1002/art.27399.

46.

The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells.

Czembirek C, Eder-Czembirek C, Erovic BM, Turhani D, Spittler A, Selzer E, Pötter R, Thurnher D.

Strahlenther Onkol. 2009 May;185(5):310-7. doi: 10.1007/s00066-009-1929-4. Epub 2009 May 15.

PMID:
19440670
47.

Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound.

Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, Paschke R, Triche T, Jansen B, Selzer E.

Eur J Clin Invest. 2009 May;39(5):384-94. doi: 10.1111/j.1365-2362.2009.02105.x.

PMID:
19309323
48.

Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel.

Kornek G, Selzer E.

Curr Pharm Des. 2009;15(2):207-42. Review.

PMID:
19149613
49.

After injection into the striatum, in vitro-differentiated microglia- and bone marrow-derived dendritic cells can leave the central nervous system via the blood stream.

Hochmeister S, Zeitelhofer M, Bauer J, Nicolussi EM, Fischer MT, Heinke B, Selzer E, Lassmann H, Bradl M.

Am J Pathol. 2008 Dec;173(6):1669-81. doi: 10.2353/ajpath.2008.080234. Epub 2008 Oct 30.

50.

Murine mobilized peripheral blood stem cells have a lower capacity than bone marrow to induce mixed chimerism and tolerance.

Koporc Z, Pilat N, Nierlich P, Blaha P, Bigenzahn S, Pree I, Selzer E, Sykes M, Muehlbacher F, Wekerle T.

Am J Transplant. 2008 Oct;8(10):2025-36. doi: 10.1111/j.1600-6143.2008.02371.x.

Supplemental Content

Loading ...
Support Center